<code id='DFCFE2FCC2'></code><style id='DFCFE2FCC2'></style>
    • <acronym id='DFCFE2FCC2'></acronym>
      <center id='DFCFE2FCC2'><center id='DFCFE2FCC2'><tfoot id='DFCFE2FCC2'></tfoot></center><abbr id='DFCFE2FCC2'><dir id='DFCFE2FCC2'><tfoot id='DFCFE2FCC2'></tfoot><noframes id='DFCFE2FCC2'>

    • <optgroup id='DFCFE2FCC2'><strike id='DFCFE2FCC2'><sup id='DFCFE2FCC2'></sup></strike><code id='DFCFE2FCC2'></code></optgroup>
        1. <b id='DFCFE2FCC2'><label id='DFCFE2FCC2'><select id='DFCFE2FCC2'><dt id='DFCFE2FCC2'><span id='DFCFE2FCC2'></span></dt></select></label></b><u id='DFCFE2FCC2'></u>
          <i id='DFCFE2FCC2'><strike id='DFCFE2FCC2'><tt id='DFCFE2FCC2'><pre id='DFCFE2FCC2'></pre></tt></strike></i>

          leisure time

          leisure time

          author:hotspot    Page View:24546
          People in business and medical wardrobe in a table discussion — coverage from STAT
          Adobe

          R1 RCM, a large publicly traded technology company that helps hospitals and physicians collect money from insurers and patients, may be going private.

          Private equity firm New Mountain Capital has offered to purchase R1 for $13.75 per share, or roughly $5.8 billion in cash, according to new financial disclosures filed Monday. New Mountain Capital is R1’s second-largest investor, owning nearly one-third of the company’s shares.

          advertisement

          In response to the offer, R1 asked New Mountain Capital to “engage in good faith discussions” with its largest investor — a partnership between Ascension, the large Catholic hospital system, and private equity firm TowerBrook Capital Partners. New Mountain Capital has since held several in-person meetings with Ascension and TowerBrook throughout February, but maintained its original offer for R1. No deal has been finalized yet.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more
          Readout LOUD podcast: ALS dilemma, first MASH drug, and more
          Readout LOUD podcast: ALS dilemma, first MASH drug, and more

          Whathappenswhenanapproveddrugdoesn’twork?Whydon’tpatientswantgenetherapy?AndisMASHstillabigdeal?Weco

          read more
          Dobbs anniversary: the lost opportunity of abortion as health care
          Dobbs anniversary: the lost opportunity of abortion as health care

          NathanHoward/GettyImagesReflectingonthisfirstanniversaryoftheSupremeCourt’sdecisioninDobbstooverturn

          read more

          Calls for Trump's election interference trial to be televised part of long debate

          8:40MediamembersprepareforthearrivalofformerPresidentDonaldTrump,whoisfacingfederalchargesinconnecti